D. Fisher

B. Sandmaier, D. Maloney, J. Pagel, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma

B. Sandmaier, J. Pagel, J. Rajendran, 2019, Clinical Cancer Research.

Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: relative biological effectiveness of alpha-particle emitters in vivo.

R. E. Schenter, S. Goddu, D. Fisher, 1997, Radiation research.

Modified biokinetic model for uranium from analysis of acute exposure to UF6.

M. J. Swint, R. Kathren, D. Fisher, 1991, Health physics.

Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: the radiation dose distribution.

K. Fujimori, J. Weinstein, D. Fisher, 1991, Cancer research.

Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies.

J. Pagel, J. Rajendran, E. Nemecek, 2008, Cancer biotherapy & radiopharmaceuticals.

Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.

M. Goris, A. Murtha, S. Knox, 1999, Cancer biotherapy & radiopharmaceuticals.

Therapeutics , Targets , and Chemical Biology A Preclinical Model of CD 38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies

B. Wood, J. Pagel, T. Gooley, 2014 .

Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.

J. Pagel, J. Rajendran, E. Nemecek, 2009, Blood.

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.

D. Fisher, O. Press, P. Weiden, 2000, Cancer biotherapy & radiopharmaceuticals.

Application of the cross‐organ beta dose method for tissue dosimetry in tumor‐bearing mice treated with a 90y‐labeled immunoconjugate

B. Beatty, J. Kuhn, D. Fisher, 1994, Cancer.

High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter 223 Ra

Boyce, S. Nilsson, Ø. Bruland, 2006 .

Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.

M. Goris, M. Tempero, G. Adams, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I / II trial of iodine-131 – tositumomab ( anti-CD 20 ) , etoposide , cyclophosphamide , and autologous stem cell transplantation for relapsed B-cell lymphomas

S. A. Bush, I. Bernstein, J. Eary, 2000 .

microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.

S. Gambhir, Xiaoyuan Chen, Zhen Cheng, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome.

I. Bernstein, J. Eary, R. Storb, 1999, Blood.

Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation.

S. A. Bush, J. Eary, F. Appelbaum, 1995, Blood.

Radiation dosimetry for radioimmunotherapy. An overview of current capabilities and limitations

D. Fisher, 1994, Cancer.

for nonmyelablative allogeneic marrow grafts Bismuth-213 labeled anti-CD45 radioimmunoconjugate to condition dogs

D. Hamlin, D. Wilbur, D. Fisher, 2013 .

Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.

J. Pagel, D. Hamlin, D. Wilbur, 2013, Blood.

Melanoma Therapy via Peptide-Targeted α-Radiation

T. Quinn, D. Fisher, T. Hoffman, 2005, Clinical Cancer Research.

Selective T-cell ablation with bismuth-213–labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation

M. Brechbiel, R. Storb, B. Sandmaier, 2003 .

Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts.

M. Brechbiel, R. Storb, B. Sandmaier, 2002, Blood.

The microdosimetry of lymphocytes irradiated by alpha-particles.

D. Fisher, R. Harty, 1982, International journal of radiation biology and related studies in physics, chemistry, and medicine.

Dosimetry of radium-223 and progeny

G. Sgouros, D. Fisher, 1999 .

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.

F. Appelbaum, J. Pagel, D. Hamlin, 2011, Blood.

Imaging and treatment of B-cell lymphoma.

I. Bernstein, J. Eary, W. Nelp, 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Biodistribution and dosimetry following infusion of antibodies labeled with large amounts of 131I.

J. Eary, K. Krohn, D. Fisher, 1991, Cancer research.

Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody.

I. Bernstein, F. Appelbaum, D. Fisher, 1992, Cancer research.

Dosimetry model for radioactivity localized to intestinal mucosa.

M. Goris, W. Bolch, S. Knox, 2004, Cancer biotherapy & radiopharmaceuticals.

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.

K. Wittrup, T. Gooley, D. Hamlin, 2018, Blood.

Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody.

W. Nelp, G. Denardo, H. Goodgold, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma

B. Sandmaier, J. Pagel, J. Rajendran, 2020, Bone Marrow Transplantation.

The in vivo fate of a 211At labelled monoclonal antibody with known specificity in a murine system.

A. Vaughan, D. Fisher, W. Bateman, 1982, International journal of radiation oncology, biology, physics.

Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials.

P. Beaumier, D. Fisher, P. Weiden, 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radiolabeled antibody therapy of human B cell lymphomas.

J. Eary, W. Nelp, D. Fisher, 1991, Advances in experimental medicine and biology.

Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.

F. Appelbaum, J. Pagel, D. Hamlin, 2008, Cancer research.

Perspectives on Internal Dosimetry for Optimized Radionuclide Therapy.

D. Fisher, 2021, Cancer biotherapy & radiopharmaceuticals.

203Pb-Labeled α-Melanocyte–Stimulating Hormone Peptide as an Imaging Probe for Melanoma Detection

T. Quinn, D. Fisher, S. Figueroa, 2008, Journal of Nuclear Medicine.

Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues.

T. Quinn, D. Fisher, Y. Miao, 2006, Nuclear medicine and biology.

Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium

E. Dadachova, D. Fisher, M. Malo, 2019, Pharmaceutics.

Radium-223: From Radiochemical Development to Clinical Applications in Targeted Cancer Therapy

Ø. Bruland, R. Larsen, D. Fisher, 2008 .

Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.

R. Storb, B. Sandmaier, M. Thakar, 2009, Cancer research.

Immunosuppressive effects of (131)I-anti-CD45 antibody in unsensitized and donor antigen-presensitized H2-matched, minor antigen-mismatched murine transplant models.

I. Bernstein, D. Fisher, C. Nourigat, 2001, Cancer research.

Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque.

J. Eary, W. Nelp, F. Appelbaum, 1991, Blood.

Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse model.

M. E. Masterson, A. Scott, L. Kostakoglu, 1995, Nuclear medicine and biology.

The importance of accurate radiation dosimetry in radioimmunotherapy of cancer.

D. Fisher, C. Badger, 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies

B. Sandmaier, J. Pagel, J. Rajendran, 2020, The Journal of Nuclear Medicine.

Melanoma-Targeting Property of Y-90-Labeled Lactam-Cyclized α-Melanocyte-Stimulating Hormone Peptide.

R. Gonzalez, Jianquan Yang, D. Fisher, 2019, Cancer biotherapy & radiopharmaceuticals.

Apoferritin-templated yttrium phosphate nanoparticle conjugates for radioimmunotherapy of cancers.

Yuehe Lin, Jun Wang, Hong Wu, 2008, Journal of nanoscience and nanotechnology.

Synthesis of lutetium phosphate–apoferritin core–shell nanoparticles for potential applications in radioimmunoimaging and radioimmunotherapy of cancers

M. Engelhard, Yuehe Lin, Jun Wang, 2008 .

Melanoma therapy via peptide-targeted {alpha}-radiation.

T. Quinn, D. Fisher, T. Hoffman, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Radiation dose to non-targeted tissues of the eye during polymer-based delivery of 90Y to ocular melanoma of the choroid

W. Bolch, D. Fisher, D. Albani, 2017 .

131 I–anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in ﬁrst remission

I. Bernstein, J. Eary, F. Appelbaum, 2006 .

MIRD Pamphlet No. 17: The Dosimetry of Nonuniform Activity Distributionsâ€”Radionuclide S Values at the Voxel Level

B. Wessels, A. Brill, S. Costes, 2006 .

Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model.

F. Appelbaum, K. Krohn, J. Pagel, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.

M. Sorror, R. Storb, B. Sandmaier, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Alpha particle emitters in medicine

D. Fisher, 1989 .

Specific Energy Distributions for Alpha Emitters in the Dog Lung

D. Fisher, 1988 .

Marrow ablative and immunosuppressive effects of 131I-anti-CD45 antibody in congenic and H2-mismatched murine transplant models.

I. Bernstein, F. Appelbaum, D. Fisher, 1999, Blood.

131 I-Anti-CD45 Antibody Plus Busulfan/Cyclophosphamide in Matched Related Transplants for Acute Myeloid Leukemia in First Remission.

I. Bernstein, J. Eary, F. Appelbaum, 2004 .

Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma

B. Sandmaier, D. Maloney, T. Gooley, 2021, Blood advances.

The Effect of Albumin-Binding Moiety on Tumor Targeting and Biodistribution Properties of 67Ga-Labeled Albumin Binder-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides.

F. Gallazzi, D. Fisher, Y. Miao, 2021, Cancer biotherapy & radiopharmaceuticals.

Radioimmunotherapy Targeting IGF2R on Canine-Patient-Derived Osteosarcoma Tumors in Mice and Radiation Dosimetry in Canine and Pediatric Models

E. Dadachova, M. Uppalapati, D. Fisher, 2021, Pharmaceuticals.

Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.

B. Wessels, D. Fisher, H. Breitz, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.

I. Bernstein, J. Eary, W. Nelp, 1993, The New England journal of medicine.

Anti-CD45 Radioimmunotherapy with 90Y but Not 177Lu Is Effective Treatment in a Syngeneic Murine Leukemia Model

J. Pagel, T. Gooley, D. Hamlin, 2014, PloS one.

Performance testing of radiobioassay laboratories: In vitro measurements (urinalysis): Final report

J. A. Maclellan, R. Traub, D. Fisher, 1988 .

Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation.

M. Brechbiel, R. Storb, B. Sandmaier, 2003, Blood.

Practical Tools for Patient-specific Characterization and Dosimetry of Radiopharmaceutical Extravasation

M. Long, D. Fisher, D. Osborne, 2022, Health physics.

Assessment of Accidental Intakes of Uranyl Acetylacetonate (UAA)

D. Fisher, J. Briant, 1994 .

Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP.

H. Deeg, B. Sandmaier, F. Appelbaum, 1992, Blood.

Phase II Trial of Yttrium-90-DOTA-Biotin Pretargeted by NR-LU-10 Antibody / Streptavidin in Patients with Metastatic Colon Cancer 1

M. Goris, M. Tempero, G. Adams, 2000 .

Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome

I. Bernstein, J. Eary, R. Storb, 1999 .

Internal radiation dosimetry for clinical testing of radiolabeled monoclonal antibodies

R. Hill, D. Fisher, J. Durham, 1990 .

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas

I. Bernstein, J. Eary, W. Nelp, 1995, The Lancet.

131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin’s lymphoma: radiation dose to the testes

J. Pagel, J. Rajendran, T. Gooley, 2012, Nuclear medicine communications.

MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy*

B. Wessels, J. Roeske, M. McDevitt, 2010, Journal of Nuclear Medicine.

Small-scale (sub-organ and cellular level) alpha-particle dosimetry methods using an iQID digital autoradiography imaging system

K. Vetter, B. Miller, Youngho Seo, 2022, Scientific Reports.

Direct Interstitial Treatment of Solid Tumors Using an Injectable Yttrium-90-Polymer Composite

D. Fisher, C. Maitz, J. Fidel, 2020, Cancer biotherapy & radiopharmaceuticals.

Synthesis and characterization of multiply-tyrosinated, multiply-iodinated somatostatin analogs.

J. Fuselier, D. Coy, E. Woltering, 1999, The journal of peptide research : official journal of the American Peptide Society.

TREATMENT OF B‐CELL LYMPHOMA WITH I‐131 LABELED MURINE MONOCLONAL ANTIBODIES.: P10

I. Bernstein, J. Eary, W. Nelp, 1987 .

The MIRD perspective 1999. Medical Internal Radiation Dose Committee.

B. Wessels, R. Loevinger, Charkes Nd, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.

S. A. Bush, I. Bernstein, J. Eary, 2000, Blood.

131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

H. Deeg, M. Maris, R. Storb, 2005 .

WR2721 protection of bone marrow in 131I-labeled antibody therapy.

I. Bernstein, J. Rasey, D. Fisher, 1991, Radiation research.

Evaluation of health effects in Sequoyah Fuels Corporation workers from accidental exposure to uranium hexafluoride

M. J. Swint, R. Kathren, D. Fisher, 1990 .

-Melanocyte–Stimulating Hormone Peptide Analog in Murine and Human Melanoma-Bearing Mouse Models

T. Quinn, D. Fisher, T. Hoffman, 2004 .

Experiences with high dose radiopeptide therapy: the health physics perspective.

E. Woltering, D. Fisher, L. Anthony, 1999, Health physics.

ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals

W E Bolch, Y Yonekura, Y. Yonekura, 2019, Annals of the ICRP.

Radiation effect in mouse skin: dose fractionation and wound healing.

H. Withers, D. Fisher, R. Gorodetsky, 1990, International journal of radiation oncology, biology, physics.

Estimated toxicity of Ca-DTPA to the human fetus.

C. W. Mays, D. Fisher, G. Taylor, 1976, Health physics.

A non-aqueous reduction process for purifying ¹⁵³Gd produced in natural europium targets.

B. McNamara, D. Fisher, C. Soderquist, 2013, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

Ca-DTPA-induced fetal death and malformation in mice.

C. W. Mays, D. Fisher, S. Calder, 1976, Teratology.

Long-term repair in vivo of colony-forming ability and chromosomal injury in X-irradiated mouse hepatocytes.

J. Hendry, D. Scott, D. Fisher, 1988, Radiation research.

Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.

D. Maloney, F. Appelbaum, J. Pagel, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models

B. Miller, J. Pagel, D. Fisher, 2015, PloS one.

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

T. Gooley, D. Hamlin, D. Wilbur, 2017, Cancer research.

The Microdosimetry of Radon Decay Products in the Respiratory Tract

D. Fisher, T. E. Hui, J. Poston, 1990 .

INTERACTION PROFILE FOR : CESIUM , COBALT , STRONTIUM , POLYCHLORINATED BIPHENYLS , and TRICHLOROETHYLENE

H. Mehendale, R. Kathren, H. Pohl, 2002 .

MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- and 90Y-Ibritumomab Tiuxetan

Sui Shen, S. Shen, R. Meredith, 2009, Journal of Nuclear Medicine.

CARCINOGENESIS FROM INHALED 239PuO2 IN BEAGLES: EVIDENCE FOR RADIATION HOMEOSTASIS AT LOW DOSES?

D. Fisher, R. Weller, 2010, Health physics.

High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.

J. Eary, D. Maloney, F. Appelbaum, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.

R. Storb, B. Sandmaier, F. Appelbaum, 2009, Blood.

Allogeneic hematopoietic cell transplantation after conditioning with 131 I – anti-CD 45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

R. Storb, B. Sandmaier, F. Appelbaum, 2009 .

Direct analysis of quantal radiation response data.

H D Thames, K. Ang, H. Thames, 1986, International journal of radiation biology and related studies in physics, chemistry, and medicine.

Dose fractionation and hepatocyte clonogens: alpha/beta congruent to 1-2 Gy, and beta decreases with increasing delay before assay.

J. Hendry, D. Fisher, 2010, Radiation research.

High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.

J. Eary, J. Rajendran, D. Fisher, 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

B. Wood, J. Pagel, T. Gooley, 2014, Cancer research.

I-Anti-CD 45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome

I. Bernstein, J. Eary, R. Storb, 1999 .

Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA

B. Sandmaier, K. Wittrup, J. Pagel, 2020, Molecular Cancer Therapeutics.

131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.

I. Bernstein, J. Eary, F. Appelbaum, 2006, Blood.

Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.

K. Wittrup, T. Gooley, D. Hamlin, 2016, Cancer research.

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.

J. Pagel, D. Hamlin, D. Wilbur, 2010, Blood.

90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.

G. Griffiths, D. Goldenberg, R. Sharkey, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

High Dose Radiolabeled Antibody Therapy of Lymphoma 1

I. Bernstein, J. Eary, W. Nelp, 2006 .

Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.

Brian W. Miller, John M. Pagel, Brenda M. Sandmaier, 2015, Medical physics.

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.

S. A. Bush, I. Bernstein, J. Eary, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia

R. Storb, B. Sandmaier, F. Appelbaum, 2019, Haematologica.

Effects of propylthiouracil on the biodistribution of an iodine-131-labeled anti-myeloid antibody in normal dogs: dosimetry and clinical implications.

I. Bernstein, J. Eary, B. Sandmaier, 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A phase II trial evaluating the efficacy of high‐dose Radioiodinated Tositumomab (Anti‐CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high‐risk relapsed or refractory non‐hodgkin lymphoma

F. Appelbaum, J. Pagel, J. Rajendran, 2020, American journal of hematology.

A Myeloablative Regimen Incorporating Radiolabeled Anti-CD45 (BC8) Antibody Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Advanced Acute Myeloid Leukemia (AML).

F. Appelbaum, J. Pagel, J. Rajendran, 2004 .

High-dose radioimmunotherapy of B cell lymphomas.

J. Eary, W. Nelp, K. Krohn, 1990, Frontiers of radiation therapy and oncology.

Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.

S. Shen, A. Forero, R. Meredith, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Protein in Patients with Gastrointestinal Malignancies Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC 49 Fusion

Ruby, S. Shen, A. Forero, 2005 .

Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab

Julien Torgue, Sui Shen, Jinda Fan, 2014, The Journal of Nuclear Medicine.

Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults 60 Years Old With Relapsed or Refractory B-Cell Lymphoma

J. Eary, D. Maloney, F. Appelbaum, 2007 .

Appropriate Use of Effective Dose in Radiation Protection and Risk Assessment.

D. Fisher, F. Fahey, 2017, Health physics.

A Critical Assessment of the Linear No-Threshold Hypothesis: Its Validity and Applicability for Use in Risk Assessment and Radiation Protection.

J. Welsh, A. Brooks, P. Zanzonico, 2019, Clinical nuclear medicine.

Effective Thresholds for Induction of Skeletal Malignancies by Radionuclides

R. D. Lloyd, D. Fisher, S. Miller, 2000, Health physics.

Skeletal Lesions from Inhaled Plutonium in Beagles

J. F. Park, H. Ragan, D. Fisher, 1985 .

Ca-DTPA toxicity in the mouse fetus.

C. W. Mays, D. Fisher, G. Taylor, 1975, Health physics.

microPET Imaging of Glioma Integrin αvβ3 Expression Using 64Cu-Labeled Tetrameric RGD Peptide

S. Gambhir, Xiaoyuan Chen, Zhen Cheng, 2005 .

Model for assessing radiation dose to epithelial cells of the human respiratory tract from radon progeny

D. Fisher, A. James, T. E. Hui, 1991 .

Radionuclide Bioassay by Inductively Coupled Plasma Mass Spectrometry (ICP/MS)

D. Fisher, E. Wyse, 1994 .

Levels of 234U, 238U and 230Th in excreta of uranium mill crushermen.

D. Fisher, P. O. Jackson, R. Scherpelz, 1983, Health physics.

Internal decontamination of radiocobalt.

D. Fisher, B. G. Dunavant, 1978, Health physics.

Production of high-purity radium-223 from legacy actinium-beryllium neutron sources.

B. McNamara, D. Fisher, C. Soderquist, 2012, Current radiopharmaceuticals.

INVESTIGATION OF THE SOLUBILITY OF YELLOWCAKE IN THE LUNG OF URANIUM MILL YELLOWCAKE WORKERS BY ASSAY FOR URANIUM IN URINE AND IN VIVO PHOTON MEASUREMENTS OF INTERNALLY DEPOSITED URANIUM COMPOUNDS

D. Fisher, K. Heid, B. Robinson, 1980 .

Occupational exposures to uranium: processes, hazards, and regulations

G. A. Stoetzel, D. R. Fisher, R. H. Moore, 1981 .

MIRD Commentary: Proposed Name for a Dosimetry Unit Applicable to Deterministic Biological Effects—The Barendsen (Bd)

W. Bolch, G. Sgouros, D. Fisher, 2009, Journal of Nuclear Medicine.

Microdosimetric concepts in radioimmunotherapy.

G T Chen, J C Roeske, J L Humm, 1993, Medical physics.

Multiple-estimate monte carlo calculation of the dose rate constant for a cesium-131 interstitial brachytherapy seed.

D. Fisher, R. Wittman, 2006, Medical physics.

High dose radiolabeled antibody therapy of lymphoma.

I. Bernstein, J. Eary, W. Nelp, 1990, Cancer Research.

Localized beta dosimetry of 131I-labeled antibodies in follicular lymphoma.

I. Bernstein, J. Weinstein, J. Eary, 1992, Medical physics.

High-Dose Radioimmunotherapy of B Cell Lymphomas1

I. Bernstein, J. Eary, W. Nelp, 1989 .

Commercial Availability of Alpha-Emitting Radionuclides for Medicine

D. Fisher, 2008 .

Pretargeted Radioimmunotherapy Using an Anti-CD45 Antibody-Streptavidin Conjugate and Radiolabeled DOTA-Biotin in Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation

R. Storb, B. Sandmaier, D. Maloney, 2013 .

MIRD Pamphlet No. 24: Guidelines for Quantitative 131I SPECT in Dosimetry Applications

Michael Ljungberg, Eric C Frey, Yuni K Dewaraja, 2013, The Journal of Nuclear Medicine.

Introduction of a Polyethylene Glycol Linker Improves Uptake of 67Cu-NOTA-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide in Melanoma

D. Fisher, Y. Miao, Jingli Xu, 2023, Cancers.

Gadolinium-153 as a brachytherapy isotope

R. Flynn, S. Enger, D. Fisher, 2013, Physics in medicine and biology.

Evaluation of a Novel Pb-203-Labeled Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide for Melanoma Targeting.

R. Gonzalez, Jianquan Yang, D. Fisher, 2019, Molecular pharmaceutics.

Internal dosimetry for systemic radiation therapy.

D. Fisher, D R Fisher, 2000, Seminars in radiation oncology.

Comparison of radiation dose estimation for myeloablative radioimmunotherapy for relapsed or recurrent mantle cell lymphoma using (131)I tositumomab to that of other types of non-Hodgkin's lymphoma.

J. Eary, J. Rajendran, D. Fisher, 2004, Cancer biotherapy & radiopharmaceuticals.

Conventional and Pretargeted Radioimmunotherapy Using an Anti-Murine CD45 Monoclonal Antibody in a Syngeneic, Disseminated Murine Leukemia Model.

F. Appelbaum, J. Pagel, D. Hamlin, 2006 .

Myeloablative 131I-Tositumomab Radioimmunotherapy in Treating Non-Hodgkin's Lymphoma: Comparison of Dosimetry Based on Whole-Body Retention and Dose to Critical Organ Receiving the Highest Dose

J. Rajendran, T. Gooley, D. Fisher, 2008, Journal of Nuclear Medicine.

89Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I

V. Solomon, H. Fonge, E. Alizadeh, 2018, OncoTarget.

In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model.

J. Pagel, D. Wilbur, M. Shadman, 2014, Cancer research.

Beta emitters rhenium‐188 and lutetium‐177 are equally effective in radioimmunotherapy of HPV‐positive experimental cervical cancer

E. Dadachova, E. Revskaya, D. Fisher, 2015, Cancer medicine.

A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥60 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma.

D. Maloney, F. Appelbaum, J. Pagel, 2005 .

Safety and Efficacy of Escalating Doses of 90 Y-BC8-DOTA (Anti-CD45) Followed by Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Chemotherapy and Autologous Stem Cell Transplantation (ASCT) for High-Risk Lymphoma

D. Maloney, J. Pagel, J. Rajendran, 2018 .

MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response—Implications for Radionuclide Therapy*

George Sgouros, Stephen R Thomas, Marta Cremonesi, 2008, Journal of Nuclear Medicine.

Radiation-absorbed dose estimates to normal organs following intraperitoneal 186Re-labeled monoclonal antibody: methods and results.

D. Fisher, P. Weiden, H. Breitz, 1995, Cancer research.

Energy Distribution and the Relative Biological Effects of Internal Alpha Emitters

D. Fisher, M. E. Frazier, T. K. Andrews, 1985 .

MIRD Pamphlet No. 28, Part 1: MIRDcalc—A Software Tool for Medical Internal Radiation Dosimetry

A. Kesner, W. Bolch, D. Fisher, 2023, The Journal of Nuclear Medicine.

High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?

S. Nilsson, Ø. Bruland, R. Larsen, 2006, Clinical Cancer Research.

In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model.

J. Pagel, D. Wilbur, M. Shadman, 2014, Cancer research.

In vivo Evaluation of Free and Chelated Accelerator-produced Actinium- 225 - Radiation Dosimetry and Toxicity Results.

E. Dadachova, E. Revskaya, D. Fisher, 2018, Current radiopharmaceuticals.

High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?

S. Nilsson, Ø. Bruland, R. Larsen, 2006, Clinical Cancer Research.

Effects of Propyithiouracil on the Biodistribution of an Iodine-13 1-Labeled Anti-Myeloid Antibody in Normal Dogs : Dosimetry and Clinical Implications

I. Bernstein, J. Eary, B. Sandmaier, 2006 .

Responses of clonogenic hepatocytes to fractionated irradiation.

J. Hendry, D. Fisher, 1986 .

Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.

F. Appelbaum, J. Pagel, D. Hamlin, 2008, Cancer research.